妳/你是否也有著創立事業實現夢想或是加入創業團隊的想法，卻不知道從何開始呢？
BTBA很榮幸邀請到兩位身兼教授與執行長雙重身分的公司創辦人來分享他們的經驗，包括創業的動機，創業過程中遇到的挑戰與收穫，以及營運公司時的心路歷程。若是妳/你好奇在台灣如何將學界研究轉化成創業資源，又或是未來計畫回台創業想多了解台灣創業環境，我們邀請到了最優秀的講者，準備了最精彩的故事，分享給相信「給我一個支點以及一根足夠長的槓桿，我將舉起地球。」的每一個妳/你。(此活動以中文進行)
BTBA is thrilled to invite two distinguished individuals who wear the hats of both professors and CEOs, each having founded their own companies. They will be sharing their wealth of experiences, delving into the motivations behind their entrepreneurial journeys, the challenges faced, the rewards reaped, and the personal evolution entailed in operating a company. Whether you’re intrigued by the transformation of academic research into entrepreneurial resources in Taiwan or contemplating a return to Taiwan for entrepreneurial pursuits in the future, please join us at this event, which will be held in Mandarin Chinese.
▶️ 主題 / Topic: Exploring Academic Landscape: Entrepreneurial Spirit in Taiwan
▶️ 時間 / Time:
▶️ 活動地點/Venue: Online event，會議連結將在此問卷結束後提供並在會議幾天前寄出email提醒。
▶️ 報名連結/RSVP : https://forms.gle/AuxUhaW1q7wusrRW8
▶️ 講者 Speakers:
▶️ 活動負責人 Organizers:
Dr. Chuang is a professor at Taipei Medical University (台北醫學大學) and the CEO/founder of CytoArm Co., Ltd (賽昂生醫). Dr. Chuang completed his Ph.D. at Kaohsiung Medical University in 2010 with more than 20-year experience in multifunctional antibody drugs, novel tumor-specific T-cell technology platforms, novel protein drugs for the treatment of autoimmune diseases, and a variety of tandem repeated protein technologies that can be applied to enhance the sensitivity of immunoassay technology.
Dr. Hsu is an associate professor in the Chemistry department at National Taiwan University (台灣大學) and the founder/CEO of Leeuwenhoek Laboratories Co. Ltd (雷文虎克生技). He received his Ph.D. at the University of California San Diego and was trained as a postdoctoral fellow at Stanford University. His research is focused on using mass spectrometry to explore the chemistry of complex biological systems and clinical applications, especially human microbiota. He was selected as one of the “Top 40 Under 40” by the Analytical Scientist in 2018 and rewarded with the MOST Young Scholar Fellowship – Columbus Program (哥倫布計畫) in 2019.
Yi-En is a Novartis clinical science and innovation fellow in Boston, working on early-phase clinical trial development and operation. She moved to the U.S. for an M.S. and a Ph.D. in Pharmaceutical Science at the University of Southern California and the University of North Carolina at Chapel Hill, respectively, after her pharmacist training at Taipei Medical University in Taiwan. During Yi-En’s academic training, her research focused on the development of anti-inflammatory treatments for inflammatory diseases, including traumatic brain injury, sepsis, and acute liver injury.
Wei-Chao is currently working as a postdoctoral associate at the Broad Institute of MIT and Harvard. He holds an M.S. in Neuroscience from NYMU in Taiwan and a Ph.D. in Neurobiology from the University of Utah. During his Ph.D. studies, Wei-Chao worked on many projects that used next-generation sequencing to determine the epigenetic mechanisms and allele-specific expression effects. Furthermore, he and lab members built a startup team with the Lassonde Entrepreneur Institute to put the research findings into practice. In 2019, he relocated to Boston to work at Amgen. Presently, he is studying the mechanisms of neuropsychiatric disorders through mouse models at the Broad Institute.